Transperineal laser ablation as treatment for benign prostatic obstruction: Safety, feasibility and functional outcomes—A pilot study
BJUI Compass · 2024-01 · 5 (1) · 52-59
DOI: 10.1002/bco2.278 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJUI Compass, online erschienen am 24.08.2023. Verfasst von Rob van Kollenburg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Urology Amsterdam University Medical Centres Amsterdam The Netherlands. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Standard surgical treatment for lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO) requires anaesthesia and hospitalization. Transperineal laser ablation (TPLA) is a novel minimally invasive treatment for BPO, which has been performed using local anaesthetics and conscious sedation.
Objectives
The aim of this study is to assess safety, feasibility and functional outcomes of TPLA for the treatment of LUTS in men fit also for standard surgery.
Methods
This prospective, multicentre, interventional pilot study included 20 patients. Eligible patients were men ≥40 years of age, with urodynamically proven bladder outlet obstruction, a peak urinary flow of 5–15 mL/s and a prostate volume of 30–120 cc. All subjects underwent Soractelite™ TPLA using the Echolaser® X4 system. Two to four fibres were placed in the prostate, whereafter laser light induced coagulative necrosis. Twelve months of follow‐up included uroflowmetry, an ultrasound of the prostate and PROMs (IPSS and IIEF).
Results
Twenty patients were treated with TPLA using local anaesthetics and optional sedation. Sixteen patients were treated in an outpatient setting, using only local anaesthetics in 12 of them; four were treated in the operating room, whereof two under general anaesthesia. No device related adverse events occurred, nor did any grade ≥3 adverse events during follow‐up. Post‐TPLA, 10 men continued spontaneous voiding, and 10 men developed a urinary retention treated by a temporary indwelling catheter for 15.2 ± 3.5 days. At 12 months, Qmax improved from 9.7 ± 3.5 to 14.9 ± 6.0 ( p = 0.015), IPSS improved from 21.3 ± 5.2 to 10.9 ± 5.5 ( p < 0.0001), QoL improved from 4.9 ± 0.9 to 1.9 ± 1.1 ( p < 0.0001), IIEF‐15 total score remained stable and 11/13 patients (85%) preserved antegrade ejaculation.
Conclusions
TPLA is a safe and feasible treatment for men with LUTS due to BPO. TPLA can be performed in an outpatient setting under only local anaesthetics. Functional and quality of life outcomes improved significantly at 12 months, and erectile function remained stable.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Urology Amsterdam University Medical Centres Amsterdam The Netherlands.
- Biomedical Engineering and Physics Amsterdam University Medical Centres Amsterdam The Netherlands.
Zitieren
APA
van Kollenburg, R., van Riel, L., Bloemen, P., de Reijke, T., Beerlage, H., de Bruin, D., & Oddens, J. (2024). Transperineal laser ablation as treatment for benign prostatic obstruction: Safety, feasibility and functional outcomes—A pilot study. BJUI Compass, 5(1), 52-59. https://doi.org/10.1002/bco2.278
Vancouver
van Kollenburg R, van Riel L, Bloemen P, de Reijke T, Beerlage H, de Bruin D, et al. Transperineal laser ablation as treatment for benign prostatic obstruction: Safety, feasibility and functional outcomes—A pilot study. BJUI Compass. 2024;5(1):52-59. doi:10.1002/bco2.278
BibTeX
@article{vanKollenburg2024,
author = {van Kollenburg, Rob and van Riel, Luigi and Bloemen, Paul and de Reijke, Theo and Beerlage, Harrie and de Bruin, Daniel and Oddens, Jorg},
title = {Transperineal laser ablation as treatment for benign prostatic obstruction: Safety, feasibility and functional outcomes—A pilot study},
journal = {BJUI Compass},
year = {2024},
volume = {5},
number = {1},
pages = {52--59},
doi = {10.1002/bco2.278}
}
EUVIMED